Zevra Therapeutics (ZVRA) AI Stock Analysis

• Market Cap: $502.41M
• Dividend Yield: N/A
• Average Volume (3M): 1.42M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 158.57%
• EPS Growth: 96.76%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): 1.21
• Shares Outstanding: 56,135,090
• 10 Day Avg. Volume: 997,364
• 30 Day Avg. Volume: 1,422,250
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 5.52
• Enterprise Value/Gross Profit: 7.67
• Enterprise Value/Ebitda: -2.97
• 1Y Price Target: $24.00
• Price Target Upside: 168.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 53 Neutral
• Price Target: $9.50 ▲(6.15% Upside)

Zevra Therapeutics' overall stock score is primarily influenced by its strong revenue growth and strategic financial maneuvers, as highlighted in the earnings call. However, the stock faces significant challenges, including negative profitability, bearish technical indicators, and cash flow difficulties. Addressing these issues will be crucial for improving its financial health and stock performance.

Positive Factors

European market opportunity

Zevra filed a marketing authorization application with the European Medicines Agency for arimoclomol, marketed in the U.S. as Miplyffa, for the treatment of Niemann-Pick disease type C (NPC).

FDA approval

Zevra received FDA approval of Miplyffa in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC).

Revenue growth

Strong Miplyffa launch leads to revenue beat for third consecutive quarter.

Negative Factors

Product adoption

Adoption of Olpruva has been slower due to the mature UCD market and strong patient satisfaction with existing treatments.

Stock performance

Despite strong results for Miplyffa, ZVRA shares are down due to issues with Olpruva.

Zevra Therapeutics Business Overview & Revenue Model

Company Description

Zevra Therapeutics (ZVRA) is a biopharmaceutical company focused on developing innovative therapies for patients with rare and complex diseases. The company specializes in advancing novel treatments that target unmet medical needs, leveraging its proprietary drug development platforms. Zevra's core products include therapies aimed at neurological and metabolic disorders, with a strong emphasis on delivering effective solutions for conditions that currently lack adequate treatment options.

How the Company Makes Money

Zevra Therapeutics generates revenue primarily through the commercialization of its pharmaceutical products, which involves selling approved therapies to healthcare providers and patients. The company may also engage in licensing agreements and partnerships with larger pharmaceutical companies for the co-development and distribution of its drugs, providing additional revenue streams through upfront payments, milestone payments, and royalties on future sales. Additionally, funding from government grants and research institutions to support clinical trials can contribute to its earnings. As Zevra advances its drug candidates through clinical trials and regulatory approvals, successful product launches and market penetration are critical for driving its financial performance.

Zevra Therapeutics Financial Statement Overview

Summary

Zevra Therapeutics shows strong revenue growth and a solid gross profit margin, indicating potential for future profitability. However, challenges with negative operating margins and cash flow difficulties could impact financial stability. Improved debt-to-equity ratio suggests better leverage management, but overall profitability remains a concern.

Income Statement

Zevra Therapeutics shows a strong revenue growth rate of 52.8% in the TTM, indicating robust top-line expansion. The gross profit margin is healthy at 71.96%, reflecting efficient cost management. However, the company struggles with profitability, as evidenced by negative EBIT and EBITDA margins, suggesting operational challenges. The net profit margin has improved to 4.26% in the TTM, showing some progress in controlling expenses.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.53 in the TTM, indicating a more balanced capital structure compared to previous periods. Return on equity is modest at 3.95%, reflecting limited profitability relative to shareholder equity. The equity ratio stands at 45.74%, suggesting a stable financial position with a reasonable proportion of assets financed by equity.

Cash Flow

Zevra Therapeutics faces challenges with negative operating and free cash flows in the TTM, indicating cash flow difficulties. The free cash flow to net income ratio is slightly above 1, suggesting that the company is generating cash flow in line with its net income. However, the negative free cash flow growth rate of -24.74% highlights ongoing cash flow management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.02M	23.61M	27.46M	10.16M	28.65M	13.29M
Gross Profit	44.63M	16.20M	24.52M	9.94M	26.59M	11.98M
EBITDA	-115.16M	-76.40M	-43.54M	-25.53M	-7.89M	-5.43M
Net Income	2.64M	-105.51M	-46.05M	-26.77M	-8.55M	-12.76M
Balance Sheet
Total Assets	256.28M	178.13M	172.33M	115.53M	132.94M	11.21M
Cash, Cash Equivalents and Short-Term Investments	47.71M	69.50M	67.74M	82.85M	112.35M	4.21M
Total Debt	62.28M	60.30M	43.77M	14.12M	1.61M	70.35M
Total Liabilities	139.05M	138.46M	110.46M	40.22M	5.82M	77.62M
Stockholders Equity	117.23M	39.67M	61.86M	75.12M	127.12M	-66.41M
Cash Flow
Free Cash Flow	-46.53M	-69.67M	-33.83M	-18.81M	10.34M	-1.97M
Operating Cash Flow	-46.21M	-69.67M	-33.53M	-18.72M	10.44M	-1.94M
Investing Cash Flow	-14.35M	-22.16M	-17.39M	-36.72M	-15.52M	-33.00K
Financing Cash Flow	68.55M	82.11M	28.46M	8.35M	113.11M	2.74M

Zevra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVRA, the sentiment is Negative. The current price of 8.95 is below the 20-day moving average (MA) of 9.60, below the 50-day MA of 10.56, and above the 200-day MA of 8.78, indicating a neutral trend. The MACD of -0.48 indicates Positive momentum. The RSI at 35.13 is Neutral, neither overbought nor oversold. The STOCH value of 20.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZVRA.

Zevra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UPB	61 Neutral	$1.08B	―		―	―	―
MAZE	59 Neutral	$696.35M	―		―	―	―
RLAY	55 Neutral	$710.33M	―	-46.24%	―	-76.27%	22.77%
ZVRA	53 Neutral	$502.41M	―	3.53%	―	158.57%	96.76%
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
OMER	40 Underperform	$283.79M	―	87.26%	―	―	10.15%
SION	―	$1.06B	―		―	―	―

Zevra Therapeutics Corporate Events

Zevra Therapeutics Elects New Directors at Annual Meeting

On May 29, 2025, Zevra Therapeutics held its Annual Meeting of Stockholders where Wendy Dixon, Ph.D., and Tamara A. Favorito were elected as directors. The meeting also saw the ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. The election process was marked by the disqualification of nominees proposed by stockholder Daniel J. Mangless due to non-compliance with legal requirements and company bylaws, ensuring the election of the company’s preferred candidates.